Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 5, 2016, Pages 994-1002

  Reyes Soffer, Gissette ^a   Millar, John S ^b   Ngai, Colleen ^a   Jumes, Patricia ^c   Coromilas, Ellie ^a   Asztalos, Bela ^d   Johnson Levonas, Amy O ^c   Wagner, John A ^c   Donovan, Daniel S ^a   Karmally, Wahida ^a   Ramakrishnan, Rajasekhar ^a   Holleran, Stephen ^a   Thomas, Tiffany ^a   Dunbar, Richard L ^b   Degoma, Emil M ^b   Rafeek, Hashmi ^e   Baer, Amanda L ^b   Liu, Yang ^c   Lassman, Michael E ^c   Gutstein, David E ^c   Rader, Daniel J ^b   Ginsberg, Henry N ^a   more..

^a Columbia University ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DREXEL UNIVERSITY   (United States)

Author keywords

apolipoprotein A I; apolipoprotein A II; cardiovascular diseases; cholesterol ester transfer proteins; cholesterol, HDL

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; APOA2 PROTEIN, HUMAN; BIOLOGICAL MARKER; CETP PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DYSLIPIDEMIAS; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BIOMARKERS; CHOLESTEROL ESTER TRANSFER PROTEINS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXAZOLIDINONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960435630     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306680     Document Type: Article

References (38)

1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000. doi: 10.1001/jama.2009.1619
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
3. Rader DJ, Tall AR, The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012 18 1344 1346. doi: 10.1038/nm.2937
4. Barter P, Rye KA, Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin Exp Pharmacol Physiol 1994 21 663 672
5. Le Goff W, Guerin M, Chapman MJ, Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004 101 17 38
6. Schaefer EJ, Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Curr Opin Lipidol 2013 24 259 264. doi: 10.1097/MOL.0b013e3283612454
7. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628
8. Clerc RG, Stauffer A, Weibel F, Hainaut E, Perez A, Hoflack JC, Bénardeau A, Pflieger P, Garriz JM, Funder JW, Capponi AM, Niesor EJ, Mechanisms underlying off-Target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-Type calcium channels. J Hypertens 2010 28 1676 1686. doi: 10.1097/HJH.0b013e32833b1f8e
9. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
10. Nicholls SJ, Lincoff AM, Barter PJ, Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. Am Heart J 2015 170 1061 1069. doi: 10.1016/j.ahj.2015.09.007
11. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC, Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009 157 352 360.e2. doi: 10.1016/j.ahj.2008.09.022
12. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ, Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2015 386 452 460. doi: 10.1016/S0140-6736(15)60158-1
13. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P, Determining the Efficacy and Tolerability Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010 363 2406 2415. doi: 10.1056/NEJMoa1009744
14. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011 306 2099 2109. doi: 10.1001/jama.2011.1649
15. Rader DJ, deGoma EM, Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 2014 65 385 403. doi: 10.1146/annurev-med-050311-163305
16. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Björkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ, Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005 25 1057 1064. doi: 10.1161/01.ATV.0000161928.16334.dd
17. Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, Wolfe ML, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ, Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J Lipid Res 2009 50 1456 1462. doi: 10.1194/jlr.P800037-JLR200
18. Krishna R, Bergman AJ, Jin B, Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008 84 679 683. doi: 10.1038/clpt.2008.109
19. Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, Wagner JA, Luk JM, Johnson-Levonas AO, Anderson MS, Dansky HM, Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res 2012 53 540 547. doi: 10.1194/jlr.M018010
20. Asztalos BF, Sloop CH, Wong L, Roheim PS, Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993 1169 291 300
21. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ, Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000 20 2670 2676
22. Millar JS, Reyes-Soffer G, Jumes P, Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest 2015 125 2510 2522. doi: 10.1172/JCI80025
23. Ranalletta M, Bierilo KK, Chen Y, Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010 51 2739 2752. doi: 10.1194/jlr.M007468
24. Brinton EA, Eisenberg S, Breslow JL, Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991 87 536 544. doi: 10.1172/JCI115028
25. Le NA, Ginsberg HN, Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988 37 614 617
26. Brinton EA, Eisenberg S, Breslow JL, Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994 14 707 720
27. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN, Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993 91 1743 1752. doi: 10.1172/JCI116384
28. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF, Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999 103 1191 1199. doi: 10.1172/JCI5286
29. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H, Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993 92 1650 1658. doi: 10.1172/JCI116750
30. Duverger N, Rader D, Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Nagano M, Nakamura H, Brewer HB Jr., Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. Eur J Biochem 1995 227 123 129
31. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H, Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004 45 448 455. doi: 10.1194/jlr.M300198-JLR200
32. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH, Differential effects of HDL subpopulations on cellular ABCA1-And SR-BI-mediated cholesterol efflux. J Lipid Res 2005 46 2246 2253. doi: 10.1194/jlr.M500187-JLR200
33. Wang SP, Daniels E, Chen Y, Castro-Perez J, Zhou H, Akinsanya KO, Previs SF, Roddy TP, Johns DG, In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption. J Lipid Res 2013 54 2858 2865. doi: 10.1194/jlr.M041541
34. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010 30 1430 1438. doi: 10.1161/ATVBAHA.110.207142
35. Castro-Perez J, Briand F, Gagen K, Wang SP, Chen Y, McLaren DG, Shah V, Vreeken RJ, Hankemeier T, Sulpice T, Roddy TP, Hubbard BK, Johns DG, Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res 2011 52 1965 1973. doi: 10.1194/jlr.M016410
36. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A, Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992 90 1290 1295. doi: 10.1172/JCI115993
37. Luo Y, Liang CP, Tall AR, The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J Biol Chem 2001 276 24767 24773. doi: 10.1074/jbc.M100912200
38. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008 299 2777 2788. doi: 10.1001/jama.299.23.2777